presentation on management thesis

8/14/2019 Presentation on Management Thesis

1/22

SUBMITTED TO:- MR

P

PRESENTED BY:- ASHISH R

(8NBN

PRESENTATION OMANAGEMENT THE


2/22

A

Thesis on

TO STUDY PROMOTION

STRATEGY ADOPTED BY RALABORATORIES LTD RELAT

RANITIDINE-150mg (AntiulceNAGPUR CITY


3/22

SALES PROMOTION

Definition:-

Sales promotion can be defined as an ataken up to boost the sales of a product.

Purpose of Sales promotion:-

y Encourage the customers to try a new p

yAttract new customers

y Encourage the customers to use the pro

service and make them brand loyal.


4/22

INDUSTRY PROFILE

y The Indian Pharmaceutical Industry todfront rank of Indias science-based indu

y The Indian Pharma Industry is estimateworth $ 4.5 billion, growing at about 8 t

annually.y The Indian Pharmaceutical sector is hig

fragmented with more than 20,000 regiunits

y Several Indian pharmaceutical companacquired companies in the US and Euromany others .


5/22

INTRODUCTION

OBJECTIVES:-

y To study the overview of Indian PharmaceMarket.

y To study the culture of Ranbaxy Lab.

y To find out the promotional strategies usedRanbaxy with respect to Histac tab.

y To find out various promotional strategies Ranbaxy to acquire market share in Nagpu

y To study the competitors of Histac in ph

market.y To study the perceptions of Doctors on sal


6/22

LIMITATIONS:-

y The scope of study is limited to Nagpur

y There may be discrepancies in the actuathe recorded data due to misinterpretat

y

Topic is vast but availability of informattimeline is short.

y Unable to meet the decision maker of thorganization.


7/22

COMPANY PROFILE

y Ranbaxy Laboratories Limited, India's largpharmaceutical company

y Ranked 8th amongst the global generic phcompanies

y

The Company has a global footprint in 49 cworld-class manufacturing facilities in 11 cserves customers in over 125 countries.

y For the year 2008, the Company recorded of US $ 1,682 Mn,

y

R&D has a pool of over 1,200 scientists engresearch.


8/22

STRENGTHSSTRENGTHS WEAKWEAK

y Low cost of production.

y Efficient technologiesfor large number ofGenerics.

y Large pool of skilledtechnical manpower.

y Low technoCapital Goo

section.y Very low ke

y Very low leBiotechnolDrug DiscoSystems

SWOT ANALYSIS


9/22

OPPORTUNITYOPPORTUNITY THRETHRE

y Growing attention for health.

y New therapy approaches.

y Globalization

y Growing incomes.

y New diagnoses and new social

diseases.

y High Cost of dproducts and fdiscoveries.

y Stricter registrprocedures.

y High entry cosmarkets.

y High cost of samarketing.

SWOT ANALYSIS cont


10/22

MISSION & VISION STATEMERANBAXY LAB.

MISSION:-

To become a research based international pharmaceutical c

VISION:-

y Achieving customer satisfaction is fundamental to our bus

y Provide product and service of the highest quality.

y Manage our operation with high concern for strategy and e

y Be a responsible corporate citizen.


11/22

RANITIDINE-150mg

y Ranitidine-150 mg is commonly used in tPeptic Ulcer Disease (PUD) and Gastro EReflux Disease (GERD).

y HISTAC:-

HISTAC is a product name of Ranbaxy Bis made up from Ranitidine-150mg mole


12/22

COMPETITORS OF HISTAC

PRODUCT NAME COMP

ZINETAC GSK

ULTAC CIPL

ULFAST SUN PHA

RANATAC J.B.CHEM

ZORAN DR. RE


13/22

RESEARCH METHODOLO

y Sample size: 20 Doctors of different age gsituated in different parts of Nagpur city.

y Primary data was used to for the analysisdrawing conclusion.

y Secondary data was used for the study of pharma market.


14/22


15/22

Conti.

28%

72%

%

%

OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALIT


16/22

SELECTION POSSIBILITY OANTIULCERANT DRUG FOR THE

DIESESE PATIENTS

37%

3

%

32%

2

0%

%

10%

1

%

20%

2

%

30%

3

%

40%

HISTAC ZINETAC RANTAC U

SELECTION POSSIBILITY OF ANTIULCERANT DRUG FOR THE ULCER DIESE


17/22

Conti.

28%

27%

24%

21%

SELECTION POSSIBILITY OF ANTIULCERANT DRUG FOR THE ULCER DIESE


18/22

KEY PARAMETERS OF PROMOTSTRATEGY OF RANBAXY

50%

18%

8%

6%

8%

10%

KEY PARAMETERS OF PROMOTIONAL STRATEGY OF RANBA

Regular

Complem

Continu

Seminar

Educatio

CRM


19/22

FINDINGS

y Indian drug market, with their chemistry skicost manufacturing have an edge in the busifirms are arguably the worlds best in drug dewith their superiority established in the procdevelopment.

y opinion of Doctors towards Ranbaxy producquality, Good are 28% and Best is 72%

y Selection possibility of antiulcerant drug fordisease patients

Histac- 37%, Zinetac- 35%, Ranatac- 32%, Ulta

Ranbaxy give more importance to Regular pthrough MR.


20/22

CONCLUSION

y Ranbaxy has very esteemed and powerful iIndian and International pharmaceuticals.

The survey clearly showed that Ranbaxy is the Segment of Generic Drug maker markethe world Pharmaceuticals market.

Ranbaxy is having good relationship betweDistributors and Doctors.

According analysis it is found that Histac T

response than that of other brands for Ulcepatients.


21/22

Conti.

y Ranbaxy provide Continued Medical Edu(CME) tour to Doctors.

y Ranbaxy provide various Gifts and Comp

Doctors for the sales promotion.

y Ranbaxy provide latest information regarresearch products.

y Ranbaxy give more value to Regular promthrough MR because it generates lot of sa


22/22

presentation on management thesis

Documents